データ更新日：2025年03月24日
泉 浩二 （いずみ こうじ） 准教授 IZUMI, Kouji
所属組織・役職等
医薬保健研究域 医学系
教育分野
所属研究室等
学歴
【出身大学院】
金沢大学
【出身大学】
金沢大学
【取得学位】
博士（医学）
職歴
金沢大学(2001/04-2002/03)
ロチェスター大学(2010/10-2012/09)
金沢大学(2012/10-)
生年月
所属学会
日本泌尿器科学会
日本臨床腫瘍学会
日本癌治療学会
日本癌学会
日本泌尿器内視鏡学会
日本内視鏡外科学会
日本がん転移学会
日本泌尿器腫瘍学会
日本アンドロロジー学会
ホルモンと癌研究会
泌尿器科分子・細胞研究会
金沢大学十全医学会
学内委員会委員等
受賞学術賞
○ノバルティスファーマ研究助成2017年(2017)
○がん集学的治療財団 第37回一般研究助成(2016)
○第12回金沢大学十全医学会賞(2015)
○第20回日本がん転移学会研究奨励賞(2015)
○2015年度武田科学振興財団医学系研究奨励（癌領域・基礎）(2015)
○第29回北國がん基金研究活動助成(2015)
○第8回金沢市医師会金沢医学館記念医学賞(2014)
○第8回日本泌尿器科学会ヤングリサーチグラント(2014)
○上原記念財団海外リサーチフェローシップ（平成22年度）(2010)
○第7回日本臨床腫瘍学会学術集会優秀ポスター(2009)
○ノバルティスファーマ研究助成2016年(2016)
○金沢大学泌尿器科同窓会賞（平成27年度）(2015)
○金沢大学泌尿器科同窓会賞（平成23年度）(2011)
○2022年度日本泌尿器内視鏡・ロボティクス学会 学会賞(2022)
○小林がん学術振興会研究助成（公4 基礎的研究）(2019)
専門分野
専門分野キーワード
去勢抵抗性,マクロファージ,ケモカイン,アンドロゲン受容体,前立腺癌
研究課題
著書
論文
- Metastasectomy improves survival in patients with metastatic urothelial carcinoma Anticancer Res 2016
- Treatment outcome of low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma Anticancer Res 2016
- Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer Oncotarget 2016
- Aplastic anemia associated with severe hemorrhagic cystitis after radiotherapy for prostate cancer Mol Clin Oncol 2016
- Editorial Comment from Dr Izumi to Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery Int J Urol 2016
- The relationship between prostate-specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate-specific antigen levels Prostate 2015
- Editorial comment to Clinical outcomes of patients with prostate cancer in Yokosuka city Japan: A comparative study between patients detected by PSA-based population screening in Yokosuka and those detected by other than the screening Int J Urol 2015
- Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level. J Cancer Res Clin Oncol 2014
- Optimal treatment for castration-resistant prostate cancer. Asian J Androl 2014
- The role of procalcitonin in differentiation between bacterial infection and neoplastic fever in patients with advanced urological cancer Int J Urol 2014
- Editorial Comment to Predictors of benign histology in clinical T1a renal cell carcinoma tumors undergoing partial nephrectomy Int J Urol 2014
- Efficacy of Tegafur-uracil in Advanced Urothelial Cancer Patients after the Treatment Failure of Platinum-based Chemotherapy Anticancer Res 2014
- The predictive factor and antihypertensive usage for tyrosine kinase inhibitor-induced hypertension in kidney cancer patients Oncol Lett 2014
- Effects of bethanechol chloride and distigmine bromide on post-voiding residual volume in patients with underactive bladder Minerva Urol Nefrol 2014
- Targeting the androgen receptor promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med 2013
- Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9® to better battle prostate cancer progression. Oncoimmunology 2013
- Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res 2013
- Androgen receptor roles in the benign prostate hyperplasia (BPH) development. Am J Pathol 2013
- Anti-androgen receptor of ASC-J9® vs anti-androgens Casodex® or MDV3100 leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 2013
- Factors Predictive of Oncological Outcome After Nephroureterectomy: Comparison Between Laparoscopic and Open Procedures Anticancer Res 2013
- Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in bone metastatic prostate cancer patients. BJU Int 2012
- Current outcome of patients with ureteral stents in the management of malignant ureteral obstruction. J Urol 2011
- Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. Prostate Cancer Prostatic Dis 2011
- Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Res 2010
- Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer. Anticancer Res 2010
- The role of percutaneous needle biopsy in differenciation of renal tumors Jpn J Clin Oncol 2010
- Role of Surgical Resection in Adult Urological Soft Tissue Sarcoma: 25-year Experience Urol Int 2010
- Cranial nerve deficit caused by skull metastasis of prostate cancer: three Japanese castration-resistant prostate cancer cases Int J Clin Oncol 2010
- Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate 2009
- Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009
- Editorial comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men Int J Urol 2018
- Ectopic ureter accompanied by giant ureteral stone and pyonephrosis Int J Urol 2007
- Incarcerated intestinal hernia in a hernia sac of reversed ileal conduit wall protruding through the stoma Int J Urol 2007
- Seminal vesicle-rectal fistula with preceeding right acute epididymitis Urol Int 2007
- Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis Oncotarget 2017
- Tumor-associated macrophages induce migration of renal cell carcinoma cells via activation of the CCL20-CCR6 axis Cancers (Basel) 2019 査読有
- Androgen replacement therapy for cancer-related sympoms in male advanced cancer patients: study protocol for a randomized prospective trial (ARTFORM study) J Med Invest 2017
- Androgen and androgen receptor in kidney cancer. 2015
- A case of metanephric adenoma treated with laparoscopic nephrectomy. Mol Clin Oncol 2017
- CCL5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment Cancer Sci 2018
- Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized Phase III trial BMC Cancer 2017
- Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer Anticancer Res 2017
- An important step in establishing a treatment strategy for small renal masses of clear cell renal cell carcinoma based on the significance of adverse histopathologic features on tumor needle biopsy Ann Transl Med 2019 査読有
- Effectiveness of Synthetic Polymer-coated Peripherally Inserted Central Catheter in Patients With Advanced Cancer In Vivo 2019 査読有
- Prognosis of patients with prostate cancer and middle range prostate-specific antigen levels of 20–100 ng/mL Int Braz J Urol 2019 査読有
- Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells J Clin Med 2019
- Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells Prostate 2019
- Palonosetron on Days 1 and 5 Versus Granisetron Daily (Days 1-5) in Germ Cell Tumour Therapy In Vivo 2019
- CCL2 Induces Resistance to the Antiproliferative Effect of Cabazitaxel in Prostate Cancer Cells Cancer Sci 2019
- Editorial comment to Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan Int J Urol 2018
- Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer with Cisplatin-unfit Renal Function In Vivo 2018
- High Serum CA19-9 Concentration Indicates High Chemosensitivity and Better Survival in Advanced Urothelial Carcinoma Anticancer Res 2018
- Editorial comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men Int J Urol 2018
- Effectiveness and safety of pegfilgrastim in BEP teatment for patients with germ cell tumor In Vivo 2018
- Tumor necrosis factor-α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation Cancer Sci 2018
- Reply to Comment on "Kadomoto, S. et al. Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis" Cancers 2020 12, 89. Cancers (Basel) 2020 査読有
- The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer Anticancer Res 2020 査読有
- Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract Anticancer Res 2018
講演・口頭発表等
- 血清骨代謝マーカーからみる中高年男性の骨代謝におけるテストステロンの役割について(会議名：第106回日本日本泌尿器科学会総会)(2018/04/20)
- 骨代謝マーカーP1NPとTRACP-5bは前立腺癌予後予測マーカーとなる(会議名：第26回日本がん転移学会学術集会・総会)(2017)
- 去勢抵抗性前立腺癌に対するエンザルタミドとアビラテロンの有効性に関するランダム化比較試験(会議名：「第37回公益財団法人がん集学的治療研究財団・一般研究助成」研究発表会)(2017)
- 去勢抵抗性前立腺癌の治療戦略-化学療法のエビデンス-近年の報告から(会議名：第67回日本泌尿器科学会中部総会)(2017)
- 限局性前立腺癌の治療によって生じた医原性膀胱異物(会議名：第31回日本泌尿器内視鏡学会総会)(2017)
- 進行腎細胞癌に対するプレサージカル治療としてのアキシチニブの有用性(会議名：第55回日本癌治療学会学術集会)(2017)
- 尿路上皮癌薬物療法の実際・精巣腫瘍治療と男性妊孕性(会議名：第7回北陸Oncology Pharmacist研究会学術講演会)(2017)
- アンドロゲン除去療法施行前立腺癌患者における血清TGF-β1のバイオマーカーとしての有用性(会議名：第15回日本臨床腫瘍学会学術集会)(2017)
- 神経因性膀胱治療薬distigmine bromideやbethanechol chlorideは残尿量減少に寄与しているか(会議名：第30回北陸排尿障害研究会)(2017)
- Tumor-associated macrophages promote prostate cancer metastasis via CCL2-CCR2 axis-induced CCL22-CCR4 axis(会議名：American Urological Association Annual meeting)(2017)
- ニボルマブ-腎癌に対する使用経験(会議名：北陸腎癌IOセミナー)(2017)
その他（報告書など）
- 特集・腎泌尿器診療の国際標準 去勢抵抗性前立腺がんの国際比較 腎臓内科・泌尿器科 2017
- 前立腺癌における骨代謝マーカーの応用 泌尿外科 2017
- ここが聞きたい前立腺癌実地診療-CRPC治療における画像診断の実際について教えてください Prostate Cacer Front Line 2017
- 学会印象記-「第111回AUA」印象記 臨床泌尿器科 2016
- 前立腺癌の浸潤・転移におけるケモカインの役割の解明と治療およびバイオマーカーへの応用 金沢大学十全医学会誌 2015
- 自然破裂を契機として発見された腎細胞癌 臨泌 2006
- 膀胱原発悪性リンパ腫の一例 泌尿外科 2005
- 腎平滑筋肉腫の一例 泌尿外科 2004
芸術・フィールドワーク
特許
共同研究希望テーマ
科研費
競争的資金・寄付金等
共同研究・受託研究実績
A-STEP採択課題
学域・学類担当授業科目
大学院担当授業科目
○集学的治療学特論(2017)
○集学的治療学特論(2017)
○集学的治療学特論(2016)
○国際がん治療学特論(2016)
○集学的治療学特論(2016)
○国際がん治療学特論(2016)